



IPO INSIGHTS



GPT Healthcare Limited

Issue Dates - Opens: 22-02-2024 | Closes: 26-02-2024

IPO Note	<ol style="list-style-type: none"> GPT Healthcare Limited operates a chain of mid-sized, multi-specialty, full-service hospitals in Eastern India under the ILS Hospitals brand, providing integrated healthcare services focusing on secondary and tertiary care. The Company is a significant corporate healthcare provider in Eastern India, boasting a notable number of beds and hospitals.
Rating	★★ (Average)

IPO SNAPSHOT

Issue Size	₹ 525.14 Crores
Issue Type	Book Built Issue IPO
Fresh Issue	₹ 40 Crores
Offer for Sale	₹ 485.14 Crores
Face Value Per Share	₹ 10
Price Band Per Share	₹177 to ₹186
Minimum Lot Size	80 shares
Listing On	BSE, NSE
Registrar to the Issue	Link Intime India Private Ltd

IPO SNAPSHOT – GPT Healthcare Limited

About the Company

- Incorporated in 1989
- GPT Healthcare Limited operates a chain of mid-sized, multi-specialty, full-service hospitals in Eastern India under the ILS Hospitals brand, providing integrated healthcare services focusing on secondary and tertiary care.
- The Company offer an extensive range of healthcare services covering more than 35 specialties and super specialties. These include internal medicine, surgery, gynecology, pediatrics, and many more.
- The Company offers a range of healthcare services in over 35 specialties and super-specialties, including internal medicine and diabetology, nephrology (including kidney transplant), laparoscopic and general surgery, gynaecology and obstetrics, intensive care, gastroenterology, orthopaedics and joint replacement, interventional cardiology, neurology, neurosurgery, paediatrics, and neonatology.
- As at June 30, 2023, the company operates four multidisciplinary hospitals with a total capacity of 561 beds, offering a comprehensive range of healthcare services in over 35 specialties and super-specialties.
- We offer an extensive range of healthcare services covering more than 35 specialties and super specialties. These include internal medicine, surgery, gynecology, pediatrics, and many more.

Competitive Strengths

- Key regional corporate healthcare company with a strong foothold in under-penetrated and densely populated healthcare delivery markets
- 'Right-sized', full service and strategically located hospitals leading to high return on capital
- Well diversified specialty mix and location mix
- Ability to attract, train and retain quality medical professionals
- Track record of operating and financial performance and growth
- Professional management and experienced leadership
- Investment in infrastructure, processes and clinical excellence driving affordability, and a strong value proposition for stakeholders

Financials (₹ in Crores)

Particulars	31-3-2021	31-3-2022	31-03-2023	Y-o-Y
Revenue	242.75	337.42	361.04	7%
EBITDA	49	73.83	74.35	1%
EBITDA Margin	20.2%	21.9%	20.6%	
PAT	-6.03	41.66	39.09	-6%
PAT Margin	-2.5%	12.3%	10.8%	

Valuation

- Attributing Annualized FY23 Earnings asking P/E = 38.12

Peers

Company Name	P/E ratio
Global Health Limited	110.89
Krishna Institute of Medical Sciences Limited	53.05
Jupiter Life Line Hospitals Limited	102.54
Yatharth Hospital & Trauma Care Services Limited	47.80
Kovai Medical Center & Hospital Limited	24.92
Shalby Limited	47.98

Note : P/E ratio is calculated as closing share price as on 19th February , 2024.

Promoters

- GPT Sons Private limited
- Dwarika Prasad Tania
- Dr. Om Tania
- Shree Gopal Tania

Objects of the issue

- Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company from banks and financial institutions
- General Corporate purposes

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

